Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms

Polycythemia Vera Clinical Trial

— PhiNESS  

Official title:

Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02823184
• Other study ID #: CHUBX 2014/27
• Status: Completed
• Start date: April 27, 2017
• Est. completion date: April 27, 2019

Study information

• Verified date: June 2020
• Source: University Hospital, Bordeaux
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study is to evaluate the endoplasmic reticulum stress markers as predictive for response to hydroxyurea in polycythemia vera (PV) and essential thrombocythemia (ET).

Description:

The recent discovery of calreticulin mutations in myeloproliferative neoplasms point to the unexpected role of the endoplasmic reticulum biology in the pathophysiology in these diseases. Otherwise, the association of endoplasmic reticulum stress with solid cancers, in particular in resistance to chemotherapy, is well documented, contrary to hematological malignancies. The study aims to evaluate endoplasmic reticulum stress markers as predictors for the response to hydroxyurea in polycythemia vera and essential thrombocythemia patients. The main objective is to correlate endoplasmic reticulum stress (defined as splicing of XBP1 above 30%) to the rate of complete response after 6 months according to the 2009 ELN criteria. This is an observational retrospective study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 148
• Est. completion date: April 27, 2019
• Est. primary completion date: April 27, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• ET or PV patients diagnosed before acceleration phase and treated by hydroxyurea with a follow up period of at least 6 months following treatment start.

• Diagnosis criteria of PV :

• WHO criteria of PV with :

• Acquired JAK2V617F mutation > 5%

• Absence of evident cause of secondary polycythemia

• Diagnosis criteria of ET :

• Platelet count > 450 G/L

• Absence of PV or Chronic Myeloid Leukemia

• Bone marrow biopsy preferred but not necessary in absence of reactional causes (CRP and ferritin levels normal) and/or presence of acquired JAK2V617F, CALR exon 9 or MPL exon 10

• Availability of RNA sample of total leukocytes before start of treatment.

Exclusion Criteria:

In absence of clonality marker, presence of secondary cause of :

• Thrombocytosis :

• Inflammatory syndrom (CRP or SV increased)

• Iron deficiency (decreased ferritin level or increased soluble transferrin receptor level)

• Polycythemia :

• Increased or normal level of EPO in context of :

• Hypoxia, respiratory insufficiency

• Sleep apnea syndrome

• Hyperaffin hemoglobin

• Absence of treatment by hydroxyurea

• Treatment by anagrelide, P32, pipobroman, interferon without subsequent hydroxyurea treatment.

• Concommitant treatment by other cancer chemotherapy (in a context of solid cancer for example).

• Diagnostic during transformation to acute leukemia

• Treatment by hydroxyurea during less than 6 months

• Bad observance of the cytotoxic treatment

Related Conditions & MeSH terms

• Essential Thrombocythemia
• Myeloproliferative Disorders
• Neoplasms
• Polycythemia
• Polycythemia Vera
• Thrombocythemia, Essential
• Thrombocytosis

Intervention

Biological:
• RNA sample of total leukocytes before start of treatment
RNA sample of total leukocytes before start of treatment

Locations

Country	Name	City	State
France	Chu Angers	Angers
France	Ch de La Cöte Basque	Bayonne
France	Chu de Bordeaux	Bordeaux
France	Crlcc Bergonie	Bordeaux
France	Chu de Brest	Brest
France	Ch de Dax	DAX
France	Ch de Libourne	Libourne

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To correlate endoplasmic reticulum stress (defined as splicing of XBP1 above 30%) to the rate of complete response after 6 months according to the 2009 ELN criteria		After 6 months of treatment